XNAS
SKIN
Market cap121mUSD
Jul 09, Last price
0.94USD
1D
-10.18%
1Q
5.05%
IPO
-90.73%
Name
Beauty Health Co
Chart & Performance
P/E
—
P/S
0.41
EPS
—
Div Yield, %
—
Shrs. gr., 5y
31.69%
Rev. gr., 5y
20.36%
Revenues
301m
-10.02%
Net income
-10m
L-67.29%
CFO
38m
+132.43%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
The Beauty Health Company is an international enterprise focused on the conceptualization, development, production, promotion, and distribution of advanced aesthetic equipment and beauty solutions. Its leading offering is HydraFacial, a renowned skincare system that works to revitalize the complexion through a multi-step process: deep cleansing, gentle exfoliation, impurity extraction, active ingredient infusion, and intensive hydration, all powered by proprietary blends and specialized serums. Beyond this, their portfolio encompasses Syndeo, a sophisticated HydraFacial Delivery System designed to optimize every phase of the treatment and allow practitioners to tailor experiences to individual client preferences. They also provide the HydraFacial Nation App, a digital tool enabling users to gain insights into their skin's condition, explore various treatment options, and track their progress over subsequent sessions. Another key product is Keravive, a specialized treatment dedicated to fostering scalp health. The company was established in 1997 and maintains its corporate headquarters in Long Beach, California.
IPO date
Feb 10, 2020
Employees
1,034
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||